Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-MIND: Tafasitamab +/- Lenalidomide with R-CHOP in DLBCL
NCT04134936Phase 1Completed
- Sponsor
- MorphoSys AG
- Start
- Dec 2019
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 1, randomised, open-label trial of tafasitamab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by MorphoSys AG. Primary endpoint: Incidence and Severity of Treatment-emergent Adverse Events at 6 months. Started Dec 2019; status: completed.
02
Drugs
tafasitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04134936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04134936.